Drugmakers cry ‘monopoly’ as Modi govt picks 1 firm each to make over 20 key raw materials Himani Chandna © Provided by The Print
New Delhi: India’s weapon to fight its dependence on Chinese medicine imports the Production-Linked Incentive scheme may end up creating a monopoly of just a few drugmakers, and the pharma lobby has expressed its concern about this to the Narendra Modi government.
The PLI scheme launched by the government in July provides monetary incentives to increase the production of 41 critical raw materials, including active pharmaceutical ingredients (APIs), intermediates and key starting materials, distributed in four categories, that are required for manufacturing final formulations (medicines) in India.
DIPAM processing non-core asset sale of BEML, Bridge & Roof: Thakur
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
The government has given approval to drug firms includingAurobindo Pharma and Karnataka Antibiotics & Pharmaceuticals under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country. The setting up of plants under the scheme will lead to total committed investment of Rs 3,761 crore by the companies and employment generation for around 3,825 people,the Ministry of Chemicals and Fertilizers said in a statement. The applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production ofPenicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA isRs 813 crore, it added.
Aurobindo, Kinvan, K taka Antibiotics first to get PLI for drugs
While Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid
Joe C Mathew | January 22, 2021 | Updated 22:23 IST
Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products
The central government has announced the list of the first three companies - Hyderabad based Aurobindo Pharma, Kinvan Pvt Ltd, Mumbai and public sector firm Karnataka Antibiotics and Pharmaceuticals - that have qualified for financial support under the production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs), drug intermediates and active pharmaceutical ingredients (APIs).
vimarsana © 2020. All Rights Reserved.